Comparative efficacy of intravitreal aflibercept biosimilar QL1207 versus reference aflibercept in the treatment of diabetic macular edema
Both the reference aflibercept and its biosimilar QL1207 demonstrate comparable efficacy in the treatment of DME, effectively reducing macular edema, improving BCVA, and enhancing macular perfusion status.
Authors
- Gaixia Zhai (ORCID: https://orcid.org/0000-0002-9882-7780)
- Na Liu (ORCID: https://orcid.org/0000-0002-6533-7312)
- Xia Zhang (ORCID: https://orcid.org/0009-0001-5748-4371)
- Shaopeng Wang (ORCID: https://orcid.org/0000-0002-9430-8879)
Institutions
- Central Hospital of Zibo (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3389/fmed.2025.1662735
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00